Infectious Disease Clinical Trials Market Report 2026

The infectious disease clinical trials market size has grown strongly in recent years. It will grow from $15.1 billion in 2025 to $16.13 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to expansion of global infectious disease burden, increased funding for vaccine development, growth in multinational clinical trial networks, adoption of digital trial management systems, rising public health research initiatives.

The infectious disease clinical trials market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing investments in pandemic preparedness, rising use of ai-assisted patient recruitment, expansion of global trial decentralization, growing focus on accelerated regulatory approvals, increasing integration of digital biomarkers. Major trends in the forecast period include increasing adoption of data-driven trial design, rising use of decentralized clinical trial models, growing integration of real-world evidence, expansion of adaptive trial methodologies, enhanced focus on rapid pathogen response.

The expansion of healthcare infrastructure is expected to drive the growth of the infectious disease clinical trials market in the coming years. Healthcare infrastructure encompasses physical healthcare facilities, medical equipment, technologies, and a skilled workforce that collectively support healthcare delivery and enable effective disease prevention, diagnosis, and treatment. Growth in healthcare infrastructure is being driven by rising demand for advanced medical services, an increasing burden of emerging and complex diseases, and the need for well-equipped facilities along with trained professionals to ensure timely diagnosis, treatment, and preventive care. Strengthened healthcare infrastructure directly enhances clinical trial capacity by offering advanced medical facilities, specialized equipment, and improved research capabilities that are critical for conducting extensive infectious disease studies. For example, in January 2025, according to the American Hospital Association, a US-based non-profit organization, the total number of hospitals in the United States is projected to reach 6,093 by 2025, indicating steady growth in healthcare facilities nationwide. As a result, the expansion of healthcare infrastructure is contributing to the growth of the infectious disease clinical trials market.

Companies operating in the infectious disease clinical trials market are increasingly concentrating on advancing research initiatives, such as conducting phase 3 trials for antibiotic candidates, to identify rare side effects and validate optimal dosing regimens. Phase 3 trials for antibiotic candidates are late-stage studies that assess a drug’s safety and effectiveness in a large patient population while comparing its performance with existing treatments prior to regulatory approval. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, initiated a Phase 3 clinical trial for zosurabalpin, a novel tethered macrocyclic peptide antibiotic designed to target carbapenem-resistant Acinetobacter baumannii (CRAB), a major cause of severe hospital-acquired infections worldwide. Zosurabalpin features a unique mechanism of action that inhibits the transport of lipopolysaccharides required for bacterial outer membrane formation, with no resistance reported to date. The global trial is expected to enroll approximately 400 patients to evaluate its safety and efficacy compared with standard therapies. Early studies have demonstrated strong activity against multidrug-resistant bacteria, favorable tolerability, and promising pharmacokinetic properties, positioning zosurabalpin as a potential breakthrough in addressing antibiotic resistance.

In February 2025, Flourish Research LLC, a US-based multi-site clinical trial organization, acquired Diablo Clinical Research LLC for an undisclosed amount. Through this acquisition, Flourish Research LLC seeks to expand its geographic reach and therapeutic area coverage, thereby strengthening its overall clinical trial capabilities. Diablo Clinical Research LLC is a US-based company specializing in conducting infectious disease clinical trials.

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit.

North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infectious disease clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the infectious disease clinical trials market by increasing costs of imported laboratory equipment, diagnostic reagents, medical devices, and data acquisition technologies used in trial execution. Pharmaceutical and biotechnology sponsors in North America and Europe are most affected due to reliance on global supply chains, while Asia-Pacific faces higher operational costs for trial materials. These tariffs can raise study budgets and extend trial timelines. However, they are also encouraging regional trial infrastructure development, local sourcing of trial supplies, and greater adoption of digital and decentralized trial models.

The infectious disease clinical trials market research report is one of a series of new reports that provides infectious disease clinical trials market statistics, including infectious disease clinical trials industry global market size, regional shares, competitors with a infectious disease clinical trials market share, detailed infectious disease clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease clinical trials industry. This infectious disease clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Infectious disease clinical trials are systematically designed research studies conducted to assess the safety, effectiveness, and appropriate use of drugs, vaccines, or therapies aimed at treating or preventing infectious diseases. These trials follow well-defined protocols to observe participant responses and gather clinical data in controlled environments. The findings contribute to advancing medical knowledge and aid in the development of effective therapeutic and preventive solutions for infectious diseases.

The main phases of infectious disease clinical trials include phase I, phase II, phase III, and phase IV. Phase I infectious disease trials represent the initial stage of testing a new drug or vaccine, focusing on safety rather than the disease itself. The indications covered include human immunodeficiency virus, hepatitis, influenza, tuberculosis, malaria, coronavirus disease 2019 (COVID-19), and others. These trials are conducted using study designs such as randomized controlled trials, open-label studies, double-blind studies, observational studies, and cohort studies. The drug types involved include antibiotics, antivirals, antifungals, vaccines, and combination therapies, and they are carried out by pharmaceutical companies, biotechnology companies, contract research organizations, academic institutes, and other stakeholders.

The infectious disease clinical trials market consists of revenues earned by entities by providing services such as patient recruitment and enrolment, data collection and management, laboratory testing and analysis, monitoring and safety oversight and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.